Forus Health Private Limited, a medical devices company focused on developing state of the art ophthalmic devices, have announced the launch of its ROP (Retinopathy of Prematurity) imaging platform – 3nethra NEO. Forus Health was founded in 2010 with a mission to eradicate preventable blindness using technology and has successfully deployed thousands of its flagship adult retinal imaging device – 3nethra classic in 25 countries.
ROP is the leading cause of blindess in infants in the world. In India 1 out of 3 babies born less than 2000 gm develops the disease and 10% of the babies will turn blind at the age of 2 months if not treated on time. Over 3.5 Million babies are born premature in India every year and there are less than 100 ROP specialists nationwide to screen and treat this condition. K.Chandrasekhar, Founder & CEO of Forus Health said, “3nethra NEO is a result of our continued efforts in building affordable and state of the art imaging solutions for eye care. Our collaboration with Narayayana Nethralaya has helped us realise our dream of effectively building products and soultions to prevent ROP blindness in pre-term babies”.
“3nethra neo is the most affordable ROP imaging device with an integrated telemedicine platform that helps in remote diagnosis. The device costs one fourth of its nearest competitor. We have 4 design patents for this product. This not only protects our design but also makes it far superior “says Dr.Shyam Vasudeva Rao ,Founder & Director Forus Health.
“We designed 3nethra NEO to be a light weight and compact wide-angle imaging device. It has skilfully designed optics, ergonomic natural grip for easy holding and its high reliability enhanced by a unique focusing and illumination system makes it an ideal choice for neonatal ICUs” – says Padmanabha Holla, Co-Founder & VP-New Products.